Bristol-Myers Squibb reveals Active A results

Bristol-Myers Squibb has released the results of its Active A study investigating the drug Plavix.

The trial, which was sponsored by the company and Sanofi-Aventis, concentrated on patients with atrial fibrillation who could not take an oral anticoagulant medication but were at increased risk of stroke.

It found if Plavix was taken as well as aspirin, it could reduce the chance of vascular events by 11 per cent compared to if the latter was taken on its own.

Strokes were also reduced by 28 per cent, which is a primary goal of physicians treating those with atrial fibrillation.

Brain Damiels, sebior vice-president of global development and medical affairs at Bristol-Myers-Squibb, explained why the two firms sponsored the Active A trial.

“[It is] part of our ongoing commitment to investigate the full potential of Plavix ? covering a broad spectrum of patients at risk of cardiovascular events early and long-term,” he remarked.

Last month, findings published in Diabetes Care showed dapagliflozin, currently under joint development by Bristol-Myers Squibb and AstraZeneca, improved a number of key glycemic measures in patients with type two diabetes who were unresponsive to other medications.